Nanolattix
June 16, 2025
Company Presentation
Oncology
Nanolattix utilizes its innovative, proprietary Bio-Lattix technology platform in oncology therapeutics, generating a pipeline that includes 2 monoclonal antibody ADCs, 8 bispecific ADCs, and 8 RDC drug candidates with encouraging preclinical data. T320-ADC has received IND approval in the US, Australia, and China, with Phase 1 clinical trials set to begin in March 2025. Nanolattix is seeking collaborative licensing and development partnerships for global expansion.
.png)
Company HQ City:
Taiyuan
Company HQ State:
Shanxi
Company HQ Country:
China
Year Founded:
2016
Lead Product in Development:
ADC-T320
CEO
Zhican Qu
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
18
When you expect your next catalyst update?
Initial Phase I clinical trials data
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}